PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-3.31%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-6.07%
Negative gross profit growth while MRVL is at 0.59%. Joel Greenblatt would examine cost competitiveness or demand decline.
-8.06%
Negative EBIT growth while MRVL is at 131.58%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-9.04%
Negative operating income growth while MRVL is at 131.58%. Joel Greenblatt would press for urgent turnaround measures.
-1.78%
Negative net income growth while MRVL stands at 163.75%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
No Data
No Data available this quarter, please select a different quarter.
-0.79%
Negative diluted EPS growth while MRVL is at 150.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-1.47%
Share reduction while MRVL is at 0.74%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-1.44%
Reduced diluted shares while MRVL is at 0.50%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-0.16%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
-48.39%
Negative OCF growth while MRVL is at 7.54%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-53.02%
Negative FCF growth while MRVL is at 9.34%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
133.94%
Positive 10Y revenue/share CAGR while MRVL is negative. John Neff might see a distinct advantage in product or market expansion over the competitor.
38.70%
Positive 5Y CAGR while MRVL is negative. John Neff might see an underappreciated edge for the firm vs. the competitor.
28.08%
Positive 3Y CAGR while MRVL is negative. John Neff might view this as a sharp short-term edge or successful pivot strategy.
498.85%
10Y OCF/share CAGR above 1.5x MRVL's 19.57%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
175.85%
5Y OCF/share CAGR above 1.5x MRVL's 55.06%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
116.94%
3Y OCF/share CAGR similar to MRVL's 127.06%. Walter Schloss might see both benefiting from a rising tide or parallel expansions.
9620.45%
Net income/share CAGR above 1.5x MRVL's 122.30% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
187.69%
5Y net income/share CAGR 1.25-1.5x MRVL's 144.07%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
83.48%
Below 50% of MRVL's 847.46%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
25.60%
10Y equity/share CAGR at 50-75% of MRVL's 46.44%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
-7.65%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-6.64%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
597.21%
Dividend/share CAGR of 597.21% while MRVL is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
156.46%
Stable or rising mid-term dividends while MRVL is cutting. John Neff sees an edge in consistent payouts vs. the competitor.
102.64%
3Y dividend/share CAGR above 1.5x MRVL's 0.06%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
19.30%
AR growth well above MRVL's 17.57%. Michael Burry fears inflated revenue or higher default risk in the near future.
-3.88%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
1.79%
Asset growth at 50-75% of MRVL's 3.31%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
-3.87%
We have a declining book value while MRVL shows 2.72%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
21.41%
Debt growth of 21.41% while MRVL is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
-2.75%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
No Data
No Data available this quarter, please select a different quarter.